<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Tela Bio Inc — News on 6ix</title>
<link>https://6ix.com/company/tela-bio-inc</link>
<description>Latest news and press releases for Tela Bio Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/tela-bio-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c91a78dffbe2df11c264.webp</url>
<title>Tela Bio Inc</title>
<link>https://6ix.com/company/tela-bio-inc</link>
</image>
<item>
<title>TELA Bio to Announce First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/tela-bio-inc/news/tela-bio-to-announce-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/tela-bio-inc/news/tela-bio-to-announce-first-quarter-2026-financial-results</guid>
<pubDate>Tue, 21 Apr 2026 20:05:00 GMT</pubDate>
<description>MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2026 financial results on Tuesday, May 12, 2026. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conferen</description>
</item>
<item>
<title>TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/tela-bio-inc/news/tela-bio-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/tela-bio-inc/news/tela-bio-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative</description>
</item>
<item>
<title>TELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/tela-bio-inc/news/tela-bio-to-announce-fourth-quarter-and-full-year-2025-financial-results-41</link>
<guid isPermaLink="true">https://6ix.com/company/tela-bio-inc/news/tela-bio-to-announce-fourth-quarter-and-full-year-2025-financial-results-41</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>MALVERN, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on</description>
</item>
<item>
<title>TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/tela-bio-inc/news/tela-bio-announces-inducement-grants-210500985</link>
<guid isPermaLink="true">https://6ix.com/company/tela-bio-inc/news/tela-bio-announces-inducement-grants-210500985</guid>
<pubDate>Fri, 23 Jan 2026 21:05:00 GMT</pubDate>
<description>MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 14,250 shares of its common stock to five newly-hired employees, with a grant date of January 20, 2026 (the "Grant Date"). The restricted stock</description>
</item>
<item>
<title>TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/tela-bio-inc/news/tela-bio-participate-piper-sandler-133000622</link>
<guid isPermaLink="true">https://6ix.com/company/tela-bio-inc/news/tela-bio-participate-piper-sandler-133000622</guid>
<pubDate>Wed, 19 Nov 2025 13:30:00 GMT</pubDate>
<description>MALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler’s 37th Annual Healthcare Conference. TELA’s management is scheduled to present at Piper Sandler’s 37th Annual Healthcare Conference at 2:30 pm ET on December 3rd, 2025. Interested parties can access the live and archived webcast at ir.tel</description>
</item>
<item>
<title>TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/tela-bio-inc/news/tela-bio-announces-pricing-13-212100800</link>
<guid isPermaLink="true">https://6ix.com/company/tela-bio-inc/news/tela-bio-announces-pricing-13-212100800</guid>
<pubDate>Thu, 13 Nov 2025 21:21:00 GMT</pubDate>
<description>MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the pricing of an underwritten registered direct offering of 4,189,000 shares of its common stock at a price of $1.11 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 7,523,000 shares of common stock at an offering price of $1.1099 per pre-funde</description>
</item>
<item>
<title>TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility</title>
<link>https://6ix.com/company/tela-bio-inc/news/tela-bio-reports-third-quarter-210100066</link>
<guid isPermaLink="true">https://6ix.com/company/tela-bio-inc/news/tela-bio-reports-third-quarter-210100066</guid>
<pubDate>Thu, 13 Nov 2025 21:01:00 GMT</pubDate>
<description>MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $20.7 million, a 9% increase from the third quarter of 2024Revised full year 2025 revenue guidance of at least 16% growth over full year 2024 Recent Strategic Highlights Stren</description>
</item>
<item>
<title>TELA Bio to Announce Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/tela-bio-inc/news/tela-bio-announce-third-quarter-133000075</link>
<guid isPermaLink="true">https://6ix.com/company/tela-bio-inc/news/tela-bio-announce-third-quarter-133000075</guid>
<pubDate>Tue, 04 Nov 2025 13:30:00 GMT</pubDate>
<description>MALVERN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2025 financial results on Thursday, November 13, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Third Quarter Earnings Con</description>
</item>
<item>
<title>TELA Bio Appoints William Plovanic to Board of Directors</title>
<link>https://6ix.com/company/tela-bio-inc/news/tela-bio-appoints-william-plovanic-210500493</link>
<guid isPermaLink="true">https://6ix.com/company/tela-bio-inc/news/tela-bio-appoints-william-plovanic-210500493</guid>
<pubDate>Mon, 03 Nov 2025 21:05:00 GMT</pubDate>
<description>MALVERN, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MALVERN, Pa., November 3, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of William (“Bill”) Plovanic, CFA, to its Board of Directors. Mr. Plovanic brings a distinctive combination of capital markets expertise and operational leadership in medical technology. He currently serves as</description>
</item>
<item>
<title>TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran</title>
<link>https://6ix.com/company/tela-bio-inc/news/tela-bio-announces-addition-betty-200500746</link>
<guid isPermaLink="true">https://6ix.com/company/tela-bio-inc/news/tela-bio-announces-addition-betty-200500746</guid>
<pubDate>Thu, 09 Oct 2025 20:05:00 GMT</pubDate>
<description>MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Betty Jo Rocchio, DNP, RN, CRNA, CENP, EBP-C, to its Board of Directors, and the departure of Lisa Colleran, who has stepped down following five years of service on the Board. Dr. Rocchio is a nationally recognized healthcare leader and one of Modern Health</description>
</item>
<item>
<title>TELA Bio Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/tela-bio-inc/news/tela-bio-reports-second-quarter-200300638</link>
<guid isPermaLink="true">https://6ix.com/company/tela-bio-inc/news/tela-bio-reports-second-quarter-200300638</guid>
<pubDate>Mon, 11 Aug 2025 20:03:00 GMT</pubDate>
<description>MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Delivered revenue of $20.2 million in the second quarter 2025, representing growth of 26% over the prior year period and sequential growth of 9% over the first quarter of 2025;Increased demand for OviTex® and Ovi</description>
</item>
<item>
<title>TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference</title>
<link>https://6ix.com/company/tela-bio-inc/news/tela-bio-participate-canaccord-genuity-200300786</link>
<guid isPermaLink="true">https://6ix.com/company/tela-bio-inc/news/tela-bio-participate-canaccord-genuity-200300786</guid>
<pubDate>Wed, 23 Jul 2025 20:03:00 GMT</pubDate>
<description>MALVERN, Pa., July 23, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 45th Annual Growth Conference. TELA’s management is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference at 10:00 am ET on August 13th, 2025. Interested parties can access the live and archived webcast at ir</description>
</item>
<item>
<title>TELA Bio to Announce Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/tela-bio-inc/news/tela-bio-announce-second-quarter-200300702</link>
<guid isPermaLink="true">https://6ix.com/company/tela-bio-inc/news/tela-bio-announce-second-quarter-200300702</guid>
<pubDate>Mon, 21 Jul 2025 20:03:00 GMT</pubDate>
<description>MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2025 financial results on Monday, August 11, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Second Quarter Earnings Confe</description>
</item>
<item>
<title>TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/tela-bio-inc/news/tela-bio-announces-inducement-grant-200500123</link>
<guid isPermaLink="true">https://6ix.com/company/tela-bio-inc/news/tela-bio-announces-inducement-grant-200500123</guid>
<pubDate>Fri, 06 Jun 2025 20:05:00 GMT</pubDate>
<description>MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grant of an option to purchase 75,000 shares of its common stock and restric</description>
</item>
<item>
<title>TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair</title>
<link>https://6ix.com/company/tela-bio-inc/news/tela-bio-announces-european-commercial-200500928</link>
<guid isPermaLink="true">https://6ix.com/company/tela-bio-inc/news/tela-bio-announces-european-commercial-200500928</guid>
<pubDate>Tue, 03 Jun 2025 20:05:00 GMT</pubDate>
<description>Based on market research, inguinal hernia repair is the most common type of hernia repairMALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the European launch of OviTex Inguinal Reinforced Tissue Matrix, the only reinforced tissue matrix specifically engineered for laparoscopic and robotic-assisted inguinal hernia repair. This milestone</description>
</item>
<item>
<title>TELA Bio Appoints Jeffrey Blizard as President</title>
<link>https://6ix.com/company/tela-bio-inc/news/tela-bio-appoints-jeffrey-blizard-123000882</link>
<guid isPermaLink="true">https://6ix.com/company/tela-bio-inc/news/tela-bio-appoints-jeffrey-blizard-123000882</guid>
<pubDate>Mon, 02 Jun 2025 12:30:00 GMT</pubDate>
<description>Company Further Strengthens Executive Leadership Team to Drive Next Phase of GrowthMALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President of TELA Bio, effective immediately. Mr. Blizard, who has served on TELA Bio’s Board of Directors for the past year, brings deep industry experience and proven l</description>
</item>
<item>
<title>TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/tela-bio-inc/news/tela-bio-participate-2025-jefferies-200500522</link>
<guid isPermaLink="true">https://6ix.com/company/tela-bio-inc/news/tela-bio-participate-2025-jefferies-200500522</guid>
<pubDate>Thu, 22 May 2025 20:05:00 GMT</pubDate>
<description>MALVERN, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the 2025 Jefferies Global Healthcare Conference. TELA’s management is scheduled to present at the 2025 Jefferies Global Healthcare Conference at 11:05 am ET on June 5th, 2025. Interested parties can access the live and archived webcast at ir.telabio.com</description>
</item>
<item>
<title>TELA Bio Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/tela-bio-inc/news/tela-bio-reports-first-quarter-200500531</link>
<guid isPermaLink="true">https://6ix.com/company/tela-bio-inc/news/tela-bio-reports-first-quarter-200500531</guid>
<pubDate>Thu, 08 May 2025 20:05:00 GMT</pubDate>
<description>MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Delivered revenue of $18.5 million in the first quarter 2025, representing growth of 12% over the prior year period and sequential growth of 5% over the fourth quarter of 2024;Increased demand for OviTex® and OviT</description>
</item>
<item>
<title>TELA Bio to Announce First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/tela-bio-inc/news/tela-bio-announce-first-quarter-200500329</link>
<guid isPermaLink="true">https://6ix.com/company/tela-bio-inc/news/tela-bio-announce-first-quarter-200500329</guid>
<pubDate>Thu, 17 Apr 2025 20:05:00 GMT</pubDate>
<description>MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conferen</description>
</item>
<item>
<title>TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery</title>
<link>https://6ix.com/company/tela-bio-inc/news/tela-bio-announces-u-commercial-110000520</link>
<guid isPermaLink="true">https://6ix.com/company/tela-bio-inc/news/tela-bio-announces-u-commercial-110000520</guid>
<pubDate>Mon, 31 Mar 2025 11:00:00 GMT</pubDate>
<description>The OviTex PRS portfolio now includes a larger option than any human acellular dermal matrix product on the marketMALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on advancing soft-tissue reconstruction solutions, today announced the U.S. launch of larger sizes of OviTex PRS Reinforced Tissue Matrix, the only tissue-based device reinforced with polymer suture embroidery specifically engineered for plastic and re</description>
</item>
</channel>
</rss>